These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 25286559)

  • 1. [Refractory hypertension: diagnosis and treatment optimization].
    Fursov AN; Chernetsov VA; Chernov SA; Potekhin NP; Sokolianskiĭ NV; Zakharova EG; Liapkova NB
    Voen Med Zh; 2014 May; 335(5):22-5. PubMed ID: 25286559
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The first experience with the use of catheter denervation of renal arteries in patients with refractory hypertension].
    Kucherov VV; Fursov AN; Chernetsov VA; Potekhin NP; Chernov SA; Sokolianskiĭ NV; Makeeva TG; Zakharova EG
    Klin Med (Mosk); 2014; 92(11):72-4. PubMed ID: 25796951
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Endovascular radiofrequency denervation of renal arteries as an innovation method of treatment of refractory arterial hypertension. First experience in Russia].
    Danilov NM; Matchin IuG; Chazova IE
    Angiol Sosud Khir; 2012; 18(1):51-4. PubMed ID: 22836328
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Updated ESH position paper on interventional therapy of resistant hypertension.
    Schmieder RE; Redon J; Grassi G; Kjeldsen SE; Mancia G; Narkiewicz K; Parati G; Ruilope L; van de Borne P; Tsioufis C;
    EuroIntervention; 2013 May; 9 Suppl R():R58-66. PubMed ID: 23732157
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment resistant hypertension and renal sympathetic denervation: drug adherence and the consolidation of blood pressure lowering effects.
    Kjeldsen SE; Os I; Mahfoud F
    EuroIntervention; 2013 May; 9 Suppl R():R7-9. PubMed ID: 23732159
    [No Abstract]   [Full Text] [Related]  

  • 6. Pathophysiology of renal denervation procedures: from renal nerve anatomy to procedural parameters.
    Ammar S; Ladich E; Steigerwald K; Deisenhofer I; Joner M
    EuroIntervention; 2013 May; 9 Suppl R():R89-95. PubMed ID: 23732162
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Catheter-based treatment of drug-resistant hypertension].
    De Benedetti E
    Rev Med Suisse; 2011 Nov; 7(317):2242-4. PubMed ID: 22400353
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Point: Chronic activation of the sympathetic nervous system is the dominant contributor to systemic hypertension.
    Esler M; Lambert E; Schlaich M
    J Appl Physiol (1985); 2010 Dec; 109(6):1996-8; discussion 2016. PubMed ID: 20185633
    [No Abstract]   [Full Text] [Related]  

  • 9. Comments on Point:Counterpoint: The dominant contributor to systemic hypertension: Chronic activation of the sympathetic nervous system vs. Activation of the intrarenal renin-angiotensin system. Activation of the sympathetic nervous system is the dominant contributor to systemic hypertension.
    Negrao CE; Negrao MV
    J Appl Physiol (1985); 2010 Dec; 109(6):2006. PubMed ID: 21188817
    [No Abstract]   [Full Text] [Related]  

  • 10. Challenging hypertension: how to diagnose and treat resistant hypertension in daily clinical practice.
    Volpe M; Tocci G
    Expert Rev Cardiovasc Ther; 2010 Jun; 8(6):811-20. PubMed ID: 20528639
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Follow-up, study design and outcome parameters.
    Volpe M; Battistoni A; Tocci G
    EuroIntervention; 2013 May; 9 Suppl R():R96-100. PubMed ID: 23732163
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rebuttal from Navar.
    Navar LG
    J Appl Physiol (1985); 2010 Dec; 109(6):2001-2. PubMed ID: 21148351
    [No Abstract]   [Full Text] [Related]  

  • 13. Rebuttal from Esler, Lambert, and Schlaich.
    Esler M; Lambert E; Schlaich M
    J Appl Physiol (1985); 2010 Dec; 109(6):2000-1. PubMed ID: 21148350
    [No Abstract]   [Full Text] [Related]  

  • 14. Comments on Point:Counterpoint: The dominant contributor to systemic hypertension: Chronic activation of the sympathetic nervous system vs. Activation of the intrarenal renin-angiotensin system.
    Rohrwasser A
    J Appl Physiol (1985); 2010 Dec; 109(6):2007. PubMed ID: 21188818
    [No Abstract]   [Full Text] [Related]  

  • 15. Expanding the indication spectrum: renal denervation in diabetes.
    Mahfoud F; Ewen S; Ukena C; Linz D; Sobotka PA; Cremers B; Böhm M
    EuroIntervention; 2013 May; 9 Suppl R():R117-21. PubMed ID: 23732142
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Renal denervation: a plea for wisdom.
    Lantelme P; Courand PY; Pathak A
    Arch Cardiovasc Dis; 2013 Mar; 106(3):121-3. PubMed ID: 23582673
    [No Abstract]   [Full Text] [Related]  

  • 17. Renal sympathetic denervation as second-line therapy in mild resistant hypertension: a pilot study.
    Kaltenbach B; Franke J; Bertog SC; Steinberg DH; Hofmann I; Sievert H
    Catheter Cardiovasc Interv; 2013 Feb; 81(2):335-9. PubMed ID: 22807098
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potential new indications and future studies.
    Sudano I; Noll G; Luscher TF
    EuroIntervention; 2013 May; 9 Suppl R():R155-60. PubMed ID: 23732149
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Renal denervation in the treatment of drug-resistant hypertension: current knowledge and future perspectives.
    Prochnau D; Figulla HR; Surber R
    Expert Rev Med Devices; 2013 Mar; 10(2):247-56. PubMed ID: 23480093
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The "resistant hypertension team": focus on a multidisciplinary approach to hypertension.
    Potthoff SA; Rump LC; Vonend O
    EuroIntervention; 2013 May; 9 Suppl R():R48-53. PubMed ID: 23732155
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.